GO:2000272 negative regulation of signaling receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000272 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of signaling receptor activity [1,3].
• Negative regulation of signaling receptor activity is essential for preventing excessive or prolonged cellular responses to cytokines, growth factors, hormones, and antigens [1,3,4].
• Key mechanisms include SOCS-mediated degradation of receptor tyrosine kinases, phosphatases that reverse receptor phosphorylation, and decoy receptors that sequester ligands [3,4,7].
• Dysregulation of this process contributes to cancers, autoimmune diseases, and developmental disorders [1,6,7].
• CRISPR knockout, point mutation, knock-in, and overexpression models enable precise dissection of negative regulatory circuits [1,3,7].
• EDITGENE provides end-to-end CRISPR services to study negative regulation of signaling receptor activity in any cell type.
Description
Negative regulation of signaling receptor activity (GO:2000272) is a biological process that attenuates or terminates signal transduction initiated by ligand-activated receptors [1,3]. This process is critical for maintaining cellular homeostasis, preventing chronic inflammation, and avoiding uncontrolled proliferation [1,4]. In lymphocytes, negative regulation of antigen receptor signaling is essential for self-tolerance and immune resolution. In cytokine signaling, feedback inhibitors such as SOCS proteins provide a paradigm for how cells switch off receptor activity [3,4]. Understanding GO:2000272 is therefore fundamental for researchers studying immunology, cancer biology, and developmental signaling [6,7].
negative regulation of signaling receptor activity At A Glance
| GO ID | GO:2000272 |
|---|---|
| GO term | negative regulation of signaling receptor activity |
| Ontology | biological_process |
| Synonym | negative regulation of receptor activity; negative regulation of signalling receptor activity |
| Major function | Attenuation or termination of signaling receptor activity to prevent excessive cellular responses |
| Related processes | Cytokine signaling, antigen receptor signaling, TGF-beta signaling, Shh signaling |
| Key regulators | SOCS proteins, phosphatases, ubiquitin ligases, decoy receptors |
| Disease relevance | Cancer, autoimmunity, developmental disorders, chronic inflammation |
What Is GO:2000272?
According to the Gene Ontology, GO:2000272 (negative regulation of signaling receptor activity) encompasses any process that stops, prevents, or reduces the frequency, rate, or extent of a signaling receptor activity [1,3]. This includes mechanisms that directly modify the receptor (e.g., phosphorylation, ubiquitination, degradation) or indirectly modulate its ability to transmit signals (e.g., decoy receptors, ligand sequestration) [3,4,7]. The term is a biological process and applies to all signaling receptor classes, including cytokine receptors, receptor tyrosine kinases, G protein-coupled receptors, and antigen receptors [1,3,6].
Why Is negative regulation of signaling receptor activity Important in Cell Biology?
Negative regulation of signaling receptor activity is a cornerstone of cellular decision-making, ensuring that responses to external cues are transient and context-appropriate [1,3]. Without it, cells may undergo uncontrolled proliferation, chronic inflammation, or developmental defects [1,6,7]. For researchers, this process offers a rich source of therapeutic targets and biomarkers, as its dysregulation is implicated in numerous pathologies [3,4,7].
• Prevents excessive cytokine signaling that can lead to autoimmune diseases [3,4].
• Controls antigen receptor signaling to maintain immune tolerance.
• Regulates growth factor receptor activity to prevent oncogenic transformation.
• Modulates hormone signaling, impacting metabolism and reproduction.
• Shapes developmental processes such as retinal neurogenesis via Shh signaling.
• Provides feedback inhibition in TGF-beta signaling to limit fibrosis.
• Influences circadian clock gene regulation through adrenergic receptors.
• Offers targets for cancer immunotherapy and anti-inflammatory drugs [3,7].
• Enables precise CRISPR-based dissection of signaling circuits [1,3,7].
• Helps understand resistance mechanisms to targeted therapies.
What Happens During negative regulation of signaling receptor activity?
Initiation of negative feedback
In simple terms: When a receptor is activated for too long, the cell starts a process to shut it down.
Upon prolonged ligand stimulation, cells induce negative feedback regulators such as SOCS proteins, which are transcriptionally upregulated and then bind to activated receptors [3,4]. This initiation step is critical for preventing sustained signaling.
Direct receptor modification
In simple terms: The receptor itself gets tagged with chemical marks that turn it off.
Phosphatases remove activating phosphate groups from receptors, while ubiquitin ligases attach ubiquitin chains that mark receptors for degradation [3,7]. These modifications directly reduce receptor activity.
Receptor internalization and degradation
In simple terms: The receptor is pulled inside the cell and broken down.
Ubiquitinated receptors are internalized via endocytosis and sorted to lysosomes for degradation, permanently terminating signaling. This process is essential for resetting the cell's responsiveness.
Decoy and soluble receptor interference
In simple terms: Decoy molecules soak up the signal before it reaches the real receptor.
Soluble decoy receptors or ligand-binding proteins sequester ligands, preventing them from activating membrane receptors [3,4]. This extracellular mechanism provides an additional layer of negative regulation.
Cross-regulation by phosphatases and inhibitory proteins
In simple terms: Other proteins can directly block the receptor's ability to send signals.
Protein tyrosine phosphatases such as SHP-1 and lipid phosphatases like PTEN counteract activating phosphorylations, while inhibitory proteins like PIAS block STAT-mediated signaling downstream of receptors [1,3]. These cross-regulatory mechanisms ensure robust attenuation.
Key Genes Involved in GO:2000272 negative regulation of signaling receptor activity
The following genes encode proteins that directly mediate or regulate negative regulation of signaling receptor activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SOCS1 | Inhibits cytokine receptor signaling by binding JAKs | Autoimmunity, cancer, inflammation [3,4] |
| SOCS3 | Negatively regulates cytokine and growth factor receptors | Metabolic disease, cancer [3,7] |
| CISH | Cytokine-inducible SH2-containing protein, inhibits STAT5 | Immune regulation, cancer |
| PTPN6 (SHP-1) | Phosphatase that dephosphorylates activated receptors | Hematopoietic malignancies, autoimmunity |
| PTPN11 (SHP-2) | Phosphatase with context-dependent positive/negative roles | Developmental disorders, cancer |
| PTEN | Lipid phosphatase that opposes PI3K signaling | Cancer, autism spectrum disorders |
| RIP140 (NRIP1) | Nuclear receptor corepressor that inhibits hormone signaling | Metabolic disease, cancer |
| SMAD7 | Inhibitory SMAD that blocks TGF-beta receptor signaling | Fibrosis, cancer |
| FKBP12 | Binds and inhibits TGF-beta type I receptor | Developmental biology, cancer |
| SUFU | Negative regulator of Hedgehog signaling | Medulloblastoma, developmental disorders |
| PTCH1 | Patched receptor inhibits Smoothened in absence of Shh | Basal cell carcinoma, developmental defects |
| ARRDC3 | Arrestin domain-containing protein that promotes receptor degradation | Cancer, metabolic regulation |
| LRIG1 | Leucine-rich repeats and immunoglobulin-like domains 1, negative regulator of RTKs | Cancer, stem cell biology |
| SPRY2 | Sprouty homolog 2, inhibits RTK signaling | Developmental disorders, cancer |
| DUSP1 | Dual-specificity phosphatase that inactivates MAPK downstream of receptors | Inflammation, cancer |
| ERRFI1 (MIG6) | ERBB receptor feedback inhibitor 1 | Cancer, tissue homeostasis |
| USP8 | Deubiquitinase that regulates receptor recycling | Cancer, endocrine disorders |
| NEDD4 | E3 ubiquitin ligase that ubiquitinates receptors for degradation | Cancer, hypertension |
How Is negative regulation of signaling receptor activity Regulated?
Negative regulation of signaling receptor activity is itself tightly regulated at multiple levels. Transcription of negative regulators such as SOCS proteins is induced by activated STATs, creating a negative feedback loop [3,4]. Post-translational modifications, including phosphorylation and ubiquitination, control the stability and activity of these regulators. Additionally, microRNAs and long non-coding RNAs can modulate the expression of negative regulators, adding another layer of control. In developmental contexts, morphogen gradients of Shh are shaped by negative regulators like PTCH1 and SUFU.
negative regulation of signaling receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SOCS1 | Autoimmunity, cancer | Knockout mice, CRISPR KO in T cells |
| PTEN | Cancer, autism | Point mutation knock-in in cell lines |
| SMAD7 | Fibrosis, cancer | Overexpression in fibroblasts |
| SUFU | Medulloblastoma | Knockout in neural progenitors |
| RIP140 | Metabolic disease | Knockout in adipocytes |
Cancer
Loss of negative regulators of receptor signaling leads to constitutive activation of oncogenic pathways. For example, SOCS1 and SOCS3 are frequently silenced in cancers, resulting in enhanced cytokine and growth factor signaling that promotes proliferation and survival [3,7]. Similarly, mutations in PTEN or overexpression of growth factor receptors overwhelm negative feedback, driving tumorigenesis.
Autoimmune and inflammatory diseases
Defective negative regulation of antigen receptor signaling in lymphocytes contributes to autoimmunity. SOCS1 deficiency in mice causes severe inflammatory disease, highlighting its role in limiting cytokine receptor signaling [3,4]. Dysregulated TGF-beta signaling due to loss of SMAD7 is associated with fibrosis and chronic inflammation.
Developmental disorders
Proper negative regulation of Shh signaling is essential for vertebrate retinal development; disruptions lead to developmental eye defects. Mutations in SUFU or PTCH1 cause medulloblastoma and basal cell carcinoma through unchecked Hedgehog pathway activity.
Metabolic and endocrine disorders
Negative regulation of hormone signaling by RIP140 affects metabolic homeostasis; its dysregulation is linked to obesity and insulin resistance. Adrenergic receptor signaling in osteoblasts regulates clock genes, and its negative regulation impacts bone metabolism.
From negative regulation of signaling receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate cytokine receptor activity? | CRISPR knockout in HEK293 or primary cells |
| What is the effect of a patient mutation in a negative regulator? | Point mutation knock-in via CRISPR |
| How does a negative regulator interact with its target receptor? | Tagged knock-in (e.g., GFP) for imaging |
| Can overexpression of a negative regulator suppress oncogenic signaling? | CRISPRa overexpression or lentiviral overexpression |
| Which genes are essential for negative regulation in a genome-wide manner? | CRISPR library screening |
| What are the transcriptomic changes upon loss of negative regulation? | RNA-seq after knockout |
How to Study the negative regulation of signaling receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function effects on receptor activity | Identify negative regulators |
| Phosphoproteomics | Receptor phosphorylation status | Quantify signaling attenuation |
| Live-cell imaging | Receptor internalization and degradation | Visualize negative regulation dynamics |
| RNA-seq | Transcriptional changes | Map downstream pathways |
| Co-immunoprecipitation | Protein-protein interactions | Identify receptor-regulator complexes |
| Ubiquitination assays | Receptor ubiquitination | Study degradation mechanisms |
| CRISPR library screening | Genome-wide modifiers | Discover novel negative regulators |
CRISPR knockout screens
Genome-wide CRISPR knockout screens can identify genes whose loss enhances or disrupts negative regulation of signaling receptor activity. For example, screening for modifiers of cytokine signaling can reveal novel SOCS-like regulators [3,7].
Phosphoproteomics
Mass spectrometry-based phosphoproteomics quantifies changes in receptor phosphorylation upon perturbation of negative regulators, providing a direct readout of receptor activity.
Live-cell imaging
Tagged receptors and negative regulators can be visualized in real time to track internalization, degradation, and interactions using fluorescence microscopy [1,7].
Transcriptomic profiling
RNA-seq after knockout or overexpression of negative regulators reveals downstream gene expression changes, identifying pathways affected by altered receptor signaling [3,4].
How CRISPR Can Be Used to Study GO:2000272 negative regulation of signaling receptor activity
Knockout
CRISPR knockout of candidate negative regulators (e.g., SOCS1, PTEN) leads to enhanced receptor activity, confirming their role in GO:2000272 [3,7]. This approach is ideal for loss-of-function studies in cell lines and primary cells.
Point Mutation
Introducing patient-derived point mutations into negative regulator genes (e.g., PTPN11) via CRISPR base editing or HDR allows precise modeling of disease-associated variants and their impact on receptor signaling.
Knock-in
Tagged knock-in of negative regulators (e.g., GFP-SOCS3) enables real-time tracking of protein localization and dynamics, revealing how they interact with activated receptors.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of negative regulators can suppress oncogenic or inflammatory signaling, providing a gain-of-function complement to knockout studies [4,7].
How EDITGENE Supports negative regulation of signaling receptor activity Research
Researchers studying negative regulation of signaling receptor activity-related genes often need to determine whether a candidate gene is causally involved in attenuating receptor signaling. This requires precise genetic manipulation, which EDITGENE provides through custom CRISPR services.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of signaling receptor activity research.
Frequently Asked Questions About negative regulation of signaling receptor activity
What is negative regulation of signaling receptor activity?
It is a biological process (GO:2000272) that stops, prevents, or reduces the frequency, rate, or extent of signaling receptor activity [1,3].
What genes are involved in negative regulation of signaling receptor activity?
Key genes include SOCS1, SOCS3, PTPN6, PTEN, SMAD7, and SUFU, among others [3,4,6,7,8].
How does negative regulation of cytokine signaling work?
SOCS proteins are induced by cytokines and then bind to JAK kinases or receptors to inhibit further signaling [3,4].
Why is negative regulation of antigen receptor signaling important?
It prevents excessive lymphocyte activation and maintains immune tolerance.
What diseases are linked to defects in negative regulation of receptor activity?
Cancers, autoimmune diseases, developmental disorders, and metabolic diseases [1,3,6,7].
How can CRISPR be used to study negative regulation of signaling receptor activity?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of negative regulators [1,3,7].
What is the role of SOCS proteins in receptor regulation?
SOCS proteins negatively regulate cytokine and growth factor receptor signaling by inhibiting JAKs and promoting receptor degradation [3,4,7].
How does PTEN negatively regulate receptor signaling?
PTEN dephosphorylates PIP3 to oppose PI3K signaling downstream of activated receptors.
What methods are used to measure negative regulation of receptor activity?
Phosphoproteomics, live-cell imaging, RNA-seq, and ubiquitination assays are commonly used [1,7].
Can EDITGENE help create custom CRISPR models for this process?
Yes, EDITGENE offers knockout, point mutation, knock-in, overexpression, and screening services for genes in this pathway.
Conclusion
Negative regulation of signaling receptor activity (GO:2000272) is a fundamental biological process that safeguards cells against excessive signaling. Its dysregulation underlies numerous diseases, making it a prime target for research. By leveraging CRISPR technologies, researchers can dissect the molecular players and develop therapeutic strategies. EDITGENE provides comprehensive services to accelerate these discoveries.
References
- 1. Plas DR et al.. 1998. Negative regulation of antigen receptor signaling in lymphocytes.. J Mol Med (Berl) 76(8):589-95 PMID: 9694436
- 2. Hirai T. 2018. Regulation of Clock Genes by Adrenergic Receptor Signaling in Osteoblasts.. Neurochem Res 43(1):129-135 PMID: 28752422
- 3. Yasukawa H et al.. 2000. Negative regulation of cytokine signaling pathways.. Annu Rev Immunol 18:143-64 PMID: 10837055
- 4. Greenhalgh CJ et al.. 2001. Negative regulation of cytokine signaling.. J Leukoc Biol 70(3):348-56 PMID: 11527983
- 5. Augereau P et al.. 2006. Negative regulation of hormone signaling by RIP140.. J Steroid Biochem Mol Biol 102(1-5):51-9 PMID: 17056252
- 6. Miyazono K. 2000. Positive and negative regulation of TGF-beta signaling.. J Cell Sci 113 ( Pt 7):1101-9 PMID: 10704361
- 7. Kazi JU et al.. 2014. SOCS proteins in regulation of receptor tyrosine kinase signaling.. Cell Mol Life Sci 71(17):3297-310 PMID: 24705897
- 8. Gallardo V et al.. 2018. Positive and negative regulation of Shh signalling in vertebrate retinal development.. F1000Res 7 PMID: 30613383
